06
February
2023
|
10:59 AM
Europe/Amsterdam
Not intended for U.S. and UK Media
Summary
Filing for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of clinical trials, PULSAR and PHOTON / In both trials, aflibercept 8 mg demonstrated unprecedented durability results with treatment intervals of up to 16 weeks, with comparable visual acuity as well as rapid and resilient fluid control to the comparator EyleaTM (aflibercept 2 mg) through to week 48 / Safety of aflibercept 8 mg was consistent with the safety profile of Eylea (aflibercept 2 mg) / Extended treatment intervals with less injections into the eye in nAMD and DME meet an important patient need
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Bayer.com – https://www.bayer.com/media/en-us/bayer-submits-aflibercept-8-mg-for-regulatory-approval-in-two-major-retinal-eye-diseases-in-the-eu/
